Fundz

Who to call at InnoCare Pharma, and when

Fundz watches for the moments InnoCare Pharma starts buying, and tells you who to reach.

  • An alert the day InnoCare Pharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at InnoCare Pharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at InnoCare Pharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

InnoCare and KeyMed Announce License Agreement with Prolium for ICP-B02 Bispecific Antibody

Jan 20, 2025

Contract Type

agreement

BeijingBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalBiopharma

Description

InnoCare Pharma and KeyMed Biosciences have jointly entered into an exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody. The agreement includes upfront and near-term payments, other payments subject to milestones, and a minority equity stake in Prolium, as well as tiered royalties on future net sales.

Quick answer

InnoCare and KeyMed Announce License Agreement with Prolium for ICP-B02 Bispecific Antibody (January 20, 2025). InnoCare Pharma is based in Beijing, Beijing, China.

What agreement did InnoCare Pharma announce on January 20, 2025?
InnoCare Pharma and KeyMed Biosciences have jointly entered into an exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody. The agreement includes upfront and near-term payments, other payments subject to milestones, and a minority equity stake in Prolium, as well as tiered royalties on future net sales.
What does InnoCare Pharma do?
InnoCare Pharma is a leading biopharmaceutical company that focuses on the treatment of cancer and autoimmune diseases.
Where is InnoCare Pharma based?
InnoCare Pharma is based in Beijing, Beijing, China.

Source: Fundz verified event record.

Company Information

Company

InnoCare Pharma

Location

Beijing, Beijing, China

About

InnoCare Pharma is a leading biopharmaceutical company that focuses on the treatment of cancer and autoimmune diseases. The company is committed to discovering, developing, and commercializing first-in-class and best-in-class drugs to address unmet medical needs in China and globally. With branches in various cities including Beijing and Hong Kong, InnoCare is actively involved in advancing innovative therapies. They aim to improve the quality of life for patients suffering from serious health conditions.

Related People

Yi
Likely contact at this company
••••••••@••••••••

See Yi's verified email →

Ivan
Likely contact at this company
••••••••@••••••••

See Ivan's verified email →

Alina
Likely contact at this company
••••••••@••••••••

See Alina's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for InnoCare Pharma's next move

Learn about Strategic plan

InnoCare Pharma signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.